MROH2B and autoimmune disease: Given that sPIF is neuroprotective, crosses the blood–brain barrier, and already received a FAST-Track FDA approval (autoimmune diseases of non-pregnant subjects clinicaltrials.gov, NCT02239562), the clinical use could be very promising12,13,17,28,36,37.